FDA Approves Duroxonrasib (RASONQUE) for Pancreatic Cancer Patients

Salt Lake City, UT, August 27, 2026 — The U.S. Food and Drug Administration (FDA) has granted approval for Duroxonrasib, marketed under the brand name RASONQUE, a new medication intended for patients diagnosed with pancreatic cancer. This development offers a new therapeutic option with hopeful results in extending the lives of individuals battling this aggressive disease.

The approval is based on clinical studies that demonstrated the drug’s efficacy in prolonging survival among pancreatic cancer patients. Specific details regarding the exact extent of life prolongation were not provided in the initial summary.

Among those who participated in clinical trials for Duroxonrasib was Gary Wight, a resident of Utah. Wight reported experiencing positive outcomes during his participation in the trial. Further details about Wight’s specific case, including the duration of his participation or the precise nature of his positive outcomes, were not detailed in the summary.

The Huntsman Cancer Institute, located in Salt Lake City, Utah, played a role in the research and clinical trials for Duroxonrasib. The extent of the institute’s involvement, whether in early-stage research, specific phases of clinical testing, or patient recruitment, was not specified. The timeline for when the Huntsman Cancer Institute became involved or the specific contribution made by the institution were also not provided.

Pancreatic cancer is known for its challenging diagnosis and treatment, often characterized by late detection and limited effective treatment options. The introduction of RASONQUE marks a potentially significant advancement in the ongoing efforts to combat this form of cancer. Further information on the drug’s availability and prescribed treatment protocols is expected to be released.

Story summarized from the original created by Scott McKane on www.fox13now.com, see more information here.

Media gallery